Author : adminDate : 2020-05-19 17:08

HLB Chairman Jin Yang-gon reveals his ambition to take a global pharma

2020, the year HLB's grand goal began.

Chairman Yang-Gon Jin of HLB announced HLB's strategy to become a global pharma.


Chairman Jin gave details of HLB's preparations this morning for four items for global new drug development (strong new drugs, development ability, capital, and speed) during the company presentation of the 'Bio Korea 2020 Invest Fair', which was conducted online.


He said "Rivoceranib, which has been marketed as a gastric cancer treatment for 5 years in China, is a proven new drug that has obtained excellent efficacy data for numerous indications with a total of 481 research papers published”, and added “with the acquisition, Rivoceranib's royalty income from Hengrui Medicine will begin coming in in the fourth quarter of this year, and global sales will begin next year. "


"Reflecting on the past 12 years in the name of 'HLB', we actively engaged in M&A in order not to lose in the speed battle with global pharmaceutical companies." chairman also said, "with Apealea coming into the ovarian cancer treatment market, starting from Germany, it will expand sales to other European countries and the United States. ” He also expressed expectations about the COVID-19 vaccine being developed by Immunomic Therapeutics, saying "the performance of the COVID-19 vaccine will continue in the second half of next year."


"HLB is collaborating with bio companies developing new drugs in various fields such as targeted anti-cancer drugs, immuno-cancer drugs, cell therapies, sepsis, vaccines, and brain tumor drugs through subsidiaries and affiliates," said Chairman Jin.  He did not forget to emphasize that “Through the HLB Bio eco-System (HBS), which integrates the core competencies of R&D, production, regulation, licensing, marketing, and related companies in the name of HLB, it will minimize the trial and error that can occur during the development of new drugs."


Bio Korea 2020, which is on the 15th occasion, is the largest bio event in Korea designed to inform the world of the capabilities of Korea's pharmaceutical and bio industries. Numerous bio companies such as Celltrion, GC Cell, and ABL Bio participated and are proceeding online in the aftermath of COVID-19 with virtual exhibition halls.